Filtered By:
Condition: Alzheimer's

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 2642 results found since Jan 2013.

Net benefit of diagnostic tests for multistate diseases: an indicator variables approach
J Biopharm Stat. 2023 Jan 29:1-28. doi: 10.1080/10543406.2023.2169928. Online ahead of print.ABSTRACTA limitation of the common measures of diagnostic test performance, such as sensitivity and specificity, is that they do not consider the relative importance of false negative and false positive test results, which are likely to have different clinical consequences. Therefore, the use of classification or prediction measures alone to compare diagnostic tests or biomarkers can be inconclusive for clinicians. Comparing tests on net benefit can be more conclusive because clinical consequences of misdiagnoses are considered. Th...
Source: Atherosclerosis - January 30, 2023 Category: Cardiology Authors: Hani Samawi Ferdous Ahmed Gene Pennello Jingjing Yin Source Type: research

Genes, Vol. 14, Pages 353: Common Genetic Factors and Pathways in Alzheimer & rsquo;s Disease and Ischemic Stroke: Evidences from GWAS
Genes, Vol. 14, Pages 353: Common Genetic Factors and Pathways in Alzheimer’s Disease and Ischemic Stroke: Evidences from GWAS Genes doi: 10.3390/genes14020353 Authors: Wei Dong Yue Huang Alzheimer’s disease (AD) and ischemic stroke (IS) are common neurological disorders, and the comorbidity of these two brain diseases is often seen. Although AD and IS were regarded as two distinct disease entities, in terms of different etiologies and clinical presentation, recent genome-wide association studies (GWASs) revealed that there were common risk genes between AD and IS, indicating common molecu...
Source: Genes - January 30, 2023 Category: Genetics & Stem Cells Authors: Wei Dong Yue Huang Tags: Review Source Type: research

Moschus exerted protective activity against H < sub > 2 < /sub > O < sub > 2 < /sub > -induced cell injury in PC12 cells through regulating Nrf-2/ARE signaling pathways
Biomed Pharmacother. 2023 Jan 26;159:114290. doi: 10.1016/j.biopha.2023.114290. Online ahead of print.ABSTRACTThe pivotal characteristics of Alzheimer's disease (AD) are irreversible memory loss and progressive cognitive decline, eventually causing death from brain failure. In the various proposed hypotheses of AD, oxidative stress is also regarded as a symbolic pathophysiologic cascade contributing to brain diseases. Using Chinese herbal medicine may be beneficial for treating and preventing AD. As a rare and valuable animal medicine, Moschus possesses antioxidant and antiapoptotic efficacy and is extensively applied for ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 28, 2023 Category: Drugs & Pharmacology Authors: Danni Xie Ting Deng Zhenwei Zhai Tao Qin Caiyou Song Ying Xu Tao Sun Source Type: research

Associations of WWC1 variants with Alzheimer's disease and vascular dementia among rural older adults in China: A population-based study
Neurobiol Aging. 2023 Jan 8:S0197-4580(23)00003-9. doi: 10.1016/j.neurobiolaging.2023.01.003. Online ahead of print.ABSTRACTWe sought to examine the associations of common WWC1 variants with Alzheimer's disease (AD) and vascular dementia (VaD) among rural-dwelling older adults in China. This population-based study used data from the baseline assessments (March -September 2018) of MIND-China. AD and VaD were diagnosed following the international criteria. Of the 5455 participants (age≥60 years, 57.27% women), 182 were diagnosed with AD and 88 with VaD. Logistic regression analysis suggested that WWC1 rs17070145 C allele (...
Source: Neurobiology of Aging - January 20, 2023 Category: Geriatrics Authors: Chaoqun Wang Xiaolei Han Yi Dong Cuicui Liu Xiaojie Wang Tingting Hou Qihua Tan Yongxiang Wang Yifeng Du Chengxuan Qiu Source Type: research

Role of tRNA-Derived Fragments in Neurological Disorders: a Review
AbstracttRFs are small tRNA derived fragments that are emerging as novel therapeutic targets and regulatory molecules in the pathophysiology of various neurological disorders. These are derived from precursor or mature tRNA, forming different subtypes that have been reported to be involved in neurological disorders like stroke, Alzheimer ’s, epilepsy, Parkinson’s, MELAS, autism, and Huntington’s disorder. tRFs were earlier believed to be random degradation debris of tRNAs. The significant variation in the expression level of tRFs in disease conditions indicates their salient role as key players in regulation of these...
Source: Molecular Neurobiology - January 19, 2023 Category: Neurology Source Type: research

An analysis of neurovascular disease markers in the hippocampus of Tupaia chinensis at different growth stages
DiscussionIt was suggested that when the hippocampus of T. chinensis developed from day 15 to 3 months, the expression of oxidatively phosphorylated proteins and RPs would vary over time. Meanwhile, the hippocamppal protein expression profile of T. chinensis after 3 months had become stable. Moreover, the study underlines that, during the early development of the hippocampus of T. chinensis, energy demand increases while protein synthesis decreases. The mitochondria of T. chinensis changes with age, and the oxidative phosphorylation metabolic pathway of mitochondria is closely related to neurovascular diseases, such as str...
Source: Frontiers in Neurology - January 17, 2023 Category: Neurology Source Type: research

High cholesterol levels change the association of biomarkers of neurodegenerative diseases with dementia risk: Findings from a population-based cohort
This study assessed whether in a population with comorbidity of neurodegenerative and cerebrovascular disease (mixed pathology) the association of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181 (p-tau181) with dementia risk varied depending on levels of total cholesterol and apolipoprotein E (APOE) ε4 genotype.METHODS: Plasma biomarkers were measured using Simoa technology in 768 participants of a nested case-control study embedded within an ongoing population-based cohort. Logistic and spline regression models, and receiver operating characteristic curves were calculate...
Source: The Journal of Alzheimers Association - January 13, 2023 Category: Psychiatry Authors: Laura Perna Ute Mons Hannah Stocker L éon Beyer Konrad Beyreuther Kira Trares Bernd Holleczek Ben Sch öttker Robert Perneczky Klaus Gerwert Hermann Brenner Source Type: research

Blood pressure and Alzheimer's disease: A review of meta-analysis
ConclusionSBP is associated with both cerebrovascular disease and AD. Therefore, future studies should use other uncontrolled factors, such as cardiovascular diseases, diabetes, and stroke, to explain the relationship between SBP and AD.
Source: Frontiers in Neurology - January 11, 2023 Category: Neurology Source Type: research

Lecanemab: How The FDA-Approved Alzheimer ’s Drug Works And Its Possible Side Effects
A patient died from a stroke during a clinical trial for the drug, and some researchers suspect lecanemab played a part.
Source: Forbes.com Healthcare News - January 6, 2023 Category: Pharmaceuticals Authors: Arianna Johnson, Forbes Staff Tags: Innovation /innovation Healthcare /healthcare Breaking breaking-news Trending Explainer Trending-Explainer Source Type: news

FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages. Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval. “For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news

Lecanemab Linked to Death in AD Patient With Stroke Given tPA Lecanemab Linked to Death in AD Patient With Stroke Given tPA
A case report links the investigational Alzheimer ' s drug to numerous severe intracerebral hemorrhages during thrombolysis treatment.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - January 5, 2023 Category: Primary Care Tags: Cardiology News Source Type: news

Closed-Loop extracranial stimulation for enhancing cerebral blood Flow in Alzheimer ’s Disease and stroke
Abstract
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - January 1, 2023 Category: Neurology Authors: Dennis Turner, Simone Degan, Stephen Schmidt Source Type: research